Antithrombotic therapy with low molecular weight heparin in children
[ N/A ]
Tarih
2003
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The incidence of thromboembolic events in children has significantly increased in the last decade, mainly because the thromboembolic events are becoming the most common complications of the increasingly higher incidence of tertiary care managements for serious primary disorders of childhood. The current standard antithrombotic therapy in children consists of initial short-term intravenous administration of unfractionated heparin, followed by long-term oral anticoagulants. Both these drugs have several disadvantages which limit optimal treatment and prevention of thromboembolic events in children. During the last two decades, results of several large randomised clinical trials have demonstrated important specific advantages of low molecular weight heparin over unfractionated heparin for the prevention and treatment of thromboembolic events in adults. Compared to standard heparin low molecular weight heparins have superior bioavailability, a longer half life, and a dose-independent clearance, which result in a more predictable anticoagulant response. Low molecular weight heparins are administrated subcutaneously and require minimal laboratory monitoring and dose adjustment, and thus offering important benefits to children with poor venous access. Based on the available data, low molecular weight heparins seem to be an efficient and safe alternative to standard anticoagulation therapy with unfractionated heparin and oral anticoagulants.
Açıklama
Anahtar Kelimeler
anticoagulant agent, heparin, low molecular weight heparin, anticoagulation, child, childhood disease, dose response, drug bioavailability, drug clearance, drug efficacy, drug half life, human, review, thromboembolism, vascular access
Kaynak
SENDROM
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
15
Sayı
12
